Advertisement

PharmacoEconomics & Outcomes News

, Volume 825, Issue 1, pp 20–20 | Cite as

Impact of price changes after loss of exclusivity for MS treatments

Clinical study
  • 8 Downloads

Reference

  1. Hua LH, et al. The Impact of Price Reductions After Loss of Exclusivity in a Cost-Effectiveness Analysis: Fingolimod Versus Interferon Beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis. Journal of Managed Care and Specialty Pharmacy 25: No. 4, Apr 2019. Available from: URL: https://doi.org/10.18553/jmcp.2019.25.4.490

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations